Related Experiment Videos
Restricted epitope recognition by precipitin-negative anti-La/SS-B-positive sera
T Gordon1, C Mavrangelos, J McCluskey
1Department of Clinical Immunology, Flinders Medical Centre, Bedford Park, South Australia.
Arthritis and Rheumatism
|June 1, 1992
Summary
Precipitin-negative anti-La/SS-B sera exhibit unique B cell epitope recognition patterns, suggesting an early stage of autoimmune response. This distinct serologic subset may explain the absence of precipitin formation in certain patients.
Area of Science:
- Immunology
- Autoimmunity
- Molecular Biology
Background:
- Anti-La/SS-B antibodies are associated with autoimmune diseases.
- The epitope specificity of anti-La/SS-B antibodies can vary.
- Precipitin-negative sera present a diagnostic challenge in identifying specific autoantibody responses.
Purpose of the Study:
- To investigate the B cell epitope recognition patterns in precipitin-negative anti-La/SS-B-positive sera.
- To determine if these sera represent a distinct serologic subset.
- To correlate epitope recognition with autoantibody response characteristics.
Main Methods:
- Serum reactivity was assessed using recombinant La/SS-B fusion proteins.
- Specific fragments of the La/SS-B molecule (La33.3, LaA, LaC, LaL2/3) were used as antigens.
- Levels of rheumatoid factor and serum IgG were measured.
Main Results:
- Precipitin-negative sera showed restricted reactivity, primarily to N-terminal and middle regions of La/SS-B.
- None of the precipitin-negative sera reacted with the carboxy-terminal fragment (LaL2/3).
- Precipitin-positive sera demonstrated broader reactivity, including the carboxy-terminal region, and had higher rheumatoid factor and IgG levels.
Conclusions:
- Restricted epitope recognition in precipitin-negative anti-La/SS-B sera likely explains the lack of precipitin formation.
- This pattern may indicate an early or distinct phase of the autoimmune response to La/SS-B.
- Identifying these distinct serologic subsets is crucial for understanding the pathogenesis of autoimmune diseases.